Result for
Tag: variants
April 15, 2021
Rapid Detection of SARS-CoV-2 Variants of Concern, Including B.1.1.28/P.1, in British Columbia, Canada
Surveillance for variants of concern (VOC) in British Columbia, Canada identified 77 VOC samples from 2,618 SARS-CoV-2 positive samples during January to March 2021 (57 B.1.1.7, 7 B.1.351, and 13 P.1 samples). This marked the first detection of the P.1 variant in British Columbia, and the 13 P.1 samples represented an epidemiologic cluster. Matic et…
Sera Neutralizing Activities against SARS-CoV-2 and Multiple Variants Six Month after Hospitalization for COVID-19
Neutralizing activity in sera of SARS-CoV-2 infected individuals (n=104) against the variants D614G, B.1.1.7, and P.1 up to 6 months after infection was similar compared to the prototypic strain isolated originally in Wuhan, but was reduced 3-fold against the B.1.351 variant. Similar to other studies, anti-spike and anti-nucleocapsid IgG levels waned over time (2.8% reverted…
INO-4800 DNA Vaccine Induces Neutralizing Antibodies and T Cell Activity Against Global SARS-CoV-2 Variants
[Pre-print, not peer-reviewed] Neutralizing antibody activity induced by the SARS-CoV-2 vaccine candidate INO-4800 (Inovia Pharmaceuticals), a DNA-based vaccine, was reduced against variants of concern B.1.1.7 and B.1.351 compared to the wild-type strain by 2.1 and 6.9-fold, respectively. In contrast, neutralizing activity was maintained against the P.1 variant, which harbors the same E484K mutation as B.1.351…
April 13, 2021
Changes in Symptomatology, Reinfection, and Transmissibility Associated with the SARS-CoV-2 Variant B.1.1.7: An Ecological Study
B.1.1.7 infections likely cause similar symptoms compared to pre-existing variants, according to an analysis of data from the COVID-19 Symptom Study app users obtained during a period when the B.1.1.7 variant was surging in the UK (September to December 2020). Participants reported no change in symptoms or disease duration. Only 0.7% of reports indicated possible…
April 8, 2021
Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351)
Antibody responses to the B.1.351 SARS-CoV-2 variant (aka, 501Y.V2) in a cohort of patients hospitalized with COVID-19 in South Africa (n=89) were found to be robust and showed high levels of cross-reactivity against the virus strain from the first wave. Furthermore, sera from patients infected with B.1.351 also neutralized the P.1 variant (aka, 501Y.V3) first…
Neutralizing Response against Variants after SARS-CoV-2 Infection and One Dose of BNT162b2
A single dose of the Pfizer-BioNTech vaccine substantially increased neutralizing activity against SARS-CoV-2 variants B.1.1.7, B.1.351, and P.1 among healthcare workers (HCWs) previously infected with SARS-CoV-2 (n=6). Serum samples from each HCW were obtained 1-12 weeks after natural infection, immediately before vaccination, and 1-2 weeks after vaccination and were tested using a microneutralization assay containing…
TMPRSS2 and RNA-Dependent RNA Polymerase Are Effective Targets of Therapeutic Intervention for Treatment of COVID-19 Caused by SARS-CoV-2 Variants (B.1.1.7 and B.1.351)
[Pre-print, not peer-reviewed] Treatments for SARS-CoV-2 infection designed to inhibit SARS-CoV-2 transmembrane serine protease 2 (TMPRSS2) and RNA-dependent RNA-polymerase (RdRp), proteins that play a role in cell entry, were shown to suppress in vitro viral replication of both variants of concern B.1.1.7 and B.1.351 with similar effectiveness as compared to the parent SARS-CoV-2 strain. Drug…
S-Gene Target Failure as a Marker of Variant B.1.1.7 Among SARS-CoV-2 Isolates in the Greater Toronto Area, December 2020 to March 2021
The B.1.1.7 SARS-CoV-2 variant (first described in the UK) rapidly became the dominant circulating strain in the greater Toronto, Canada area between December 2020 and March 2021. Based on PCR S-gene target failure, which is strongly associated with the B.1.1.7 variant, 2% of samples were inferred to be the B.1.1.7 variant in mid-December 2020, which…
Functional Evaluation of Proteolytic Activation for the SARS-CoV-2 Variant B.1.1.7 Role of the P681H Mutation
[Pre-print, not peer-reviewed] In vitro experiments show that while the P681H mutation found in the SARS-CoV-2 B.1.1.7 variant was associated with more efficient cleavage of the Spike 1 and Spike 2 (S1/S2) subunits, this did not translate to a significant impact on cell entry or an increase in cell-to- cell spread. Lubinski et al. (Apr 8,…
April 6, 2021
A New SARS-CoV-2 Lineage That Shares Mutations with Known Variants of Concern Is Rejected by Automated Sequence Repository Quality Control
[Pre-print, not peer-reviewed] A SARS-CoV-2 variant (named B.1.x) may be an emerging lineage that has been poorly recognized due to a deletion mutation that causes the submission of its sequence to be rejected by automated sequence repository quality control in genome databases such as GISAID and Genbank. The variant, which contains a deletion in the…
Previous page Next page